RxDoctor Payments Data

Clarence Brown, MD

Dermatology · la Crosse, WINPI 1386654390

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,981 of the $2,771 with a category attached, or 71.5%. 21 manufacturers reported payments, led by AbbVie at 34.1% of the total. Reporting peaked in 2019 at $919 and has fallen 97.9% since, to $19 in 2024.

$2,771in general payments, 2019–2025

Across 101 payments — averaging $27.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$945
  • Chugai Pharmaceutical Co., Ltd.$450
  • Pfizer$373
  • Lilly USA, LLC$170
  • Regeneron Healthcare Solutions, Inc.$165
  • Merz North America, Inc.$134
  • plus $533 from 15 others
$149,622in research payments, 2019–2025

Across 28 payments — averaging $5343.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$150K

What the payments were for

  • Consulting fees$79029%
  • Food & beverage$1,98171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,771 in reported general payments places this provider in the 75th percentile of 260 dermatology providers in Wisconsin.

See all dermatology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$353,923
Medicare patients
661
Services billed
2,164

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil50$3,333
Minocycline Hcl148$1,765
Clobetasol Propionate27$1,275
Clindamycin Phosphate12$438
Betamethasone Valerate15$335
Triamcinolone Acetonide25$265
Ketoconazole11$142
CiclopiroxCiclopirox Olamine11$112
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim18$32

Paid to pharmacies, not to this prescriber.

Other dermatology in la Crosse

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →